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Abstract
Glycine N-methyltransferase (GNMT) is the most abundant methyltransferase in the liver and a master regulator of the
transmethylation flux. GNMT downregulation leads to loss of liver function progressing to fibrosis, cirrhosis, and
hepatocellular carcinoma. Moreover, GNMT deficiency aggravates cholestasis-induced fibrogenesis. To date, little is
known about the mechanisms underlying downregulation of GNMT levels in hepatic fibrosis and cirrhosis. On this
basis, microRNAs are epigenetic regulatory elements that play important roles in liver pathology. In this work, we aim
to study the regulation of GNMT by microRNAs during liver fibrosis and cirrhosis. Luciferase assay on the 3ʹUTR-Gnmt
was used to confirm in silico analysis showing that GNMT is potentially targeted by the microRNA miR-873-5p.
Correlation between GNMT and miR-873-5p in human cholestasis and cirrhosis together with miR-873-5p inhibition
in vivo in different mouse models of liver cholestasis and fibrosis [bile duct ligation and Mdr2 (Abcb4)-/- mouse] were
then assessed. The analysis of liver tissue from cirrhotic and cholestatic patients, as well as from the animal models,
showed that miR-873-5p inversely correlated with the expression of GNMT. Importantly, high circulating miR-873-5p
was also detected in cholestastic and cirrhotic patients. Preclinical studies with anti-miR-873-5p treatment in bile duct
ligation and Mdr2-/- mice recovered GNMT levels in association with ameliorated inflammation and fibrosis mainly by
counteracting hepatocyte apoptosis and cholangiocyte proliferation. In conclusion, miR-873-5p emerges as a novel
marker for liver fibrosis, cholestasis, and cirrhosis and therapeutic approaches based on anti-miR-873-5p may be
effective treatments for liver fibrosis and cholestatic liver disease.
Introduction
Glycine N-methyltransferase (GNMT) is the most
important and abundant S-adenosylmethionine (SAMe)-
dependent methyltransferase in the liver. GNMT is pre-
dominantly expressed in hepatocytes although it is also
found in other cell types such as cholangiocytes, the
epithelial cells of the bile duct1–3. Lack of GNMT induces
undesired methylation reactions leading to proliferative,
inflammatory, and profibrogenic responses that culminate
in liver disease4,5. GNMT expression is reduced in dif-
ferent liver diseases including liver cirrhosis of diverse
etiology1,6, chronic cholestatic liver disease7, hepatocel-
lular carcinoma (HCC)1, and cholangiocarcinoma2. In
agreement, Gnmt-deficient (Gnmt-/-) mice, characterized
by elevated SAMe levels, develop liver fibrosis sponta-
neously at the age of 3 months and HCC at 8 months8.
Indeed, an aberrant DNA methylation signature has been
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identified in the Gnmt-/- mouse8, underscoring the
importance of this protein as an epigenetic regulator.
Although GNMT promoter hypermethylation causes
GNMT downregulation in some HCC patients9, other
mechanisms are likely to be involved in the regulation of
this gene in liver diseases such as fibrosis or cirrhosis.
Hepatic fibrosis is the result of the wound-healing
response of the liver to repeated injury that occurs in
most types of chronic liver diseases. The injury can be
caused by the accumulation of lipids in the liver, as occurs
during non-alcoholic fatty liver disease (NAFLD), can be a
result of a toxicant or viral insult, such as excessive
alcohol consumption or hepatitis, respectively, or the
accumulation of bile acids (BA), as in chronic liver cho-
lestasis. The finding of potential molecular and pathway
targets for reverting or halting the progression of liver
fibrosis or cholestasis to cirrhosis and HCC is an emer-
ging field.
MicroRNAs (miRNAs) are highly conserved, small non-
coding RNAs that post-transcriptionally regulate gene
expression10 of essential biological processes, as well as
cellular responses11,12. In the liver, miRNA signature has
been implicated in NAFLD, cirrhosis, and liver cancer13.
The biological significance and therapeutic potential of
miRNAs in liver disease management is a rapidly growing
field.
In this study, we show that liver fibrosis progression is
associated with the repression of GNMT, which is tar-
geted by miR-873-5p in two preclinical models of liver
fibrosis and cholestasis: the bile duct ligation (BDL) and
the Mdr2 (Abcb4)-deficient mice (Mdr2-/-), respectively.
Targeting miR-873-5p in these models resulted in a
reduction of liver damage affecting mainly hepatocyte
apoptosis and cholangiocyte proliferation, through a
GNMT-dependent epigenomic mechanism. Of note, an
inverse correlation between hepatic GNMT and miR-873-
5p was identified in a cohort of cirrhotic patients with
diverse etiology. Importantly, increased circulating miR-
873-5p was also detected in serum samples from cirrhotic
and cholestatic patients. A negative correlation was found
between hepatic GNMT expression and serum levels of
miR-873-5p in a cohort of cholestatic patients according
with the fibrotic stage.
Overall, miR-873-5p emerges as a novel druggable tar-
get and a marker for liver fibrosis, cholestasis and
cirrhosis.
Results
MiR-873-5p targets Gnmt expression in mouse
hepatocytes
Understanding the mechanism underlying GNMT
repression is essential for the development of new ther-
apeutic approaches in liver fibrosis and cholestatic dis-
eases. From three independent unbiased approaches
employed (www.targetscan.org, www.ebi.ac.uk, and www.
microrna.org) only miR-873-5p appears as a common
microRNA targeting GNMT (Suppl. Fig. 1a). For func-
tional analysis of miR-873-5p, primary mouse hepato-
cytes, characterized by high levels of GNMT, were
transfected with pmir-GLO and pmir-GLO-Gnmt-3ʹUTR
both fused to a luciferase reporter gene. Transfection with
a miR-873-5p mimic (mimic-miR-873-5p) results in a
50% reduction of 3ʹUTR Gnmt reporter activity vs. those
transfected with miR-Control (Fig. 1a). Moreover, mimic-
miR-873-5p efficiently reduced mRNA and protein
GNMT levels in cultured hepatocytes (Fig. 1b). Alto-
gether, these data support miR-873-5p as a post-
transcriptional repressor of Gnmt.
MiR-873-5p inversely correlates with GNMT expression in
liver fibrosis and cholestasis
The inverse association between GNMT and miR-873-
5p expression was confirmed in different preclinical
models of liver fibrosis. Administration of carbon tetra-
chloride (CCl4) for 6 weeks induced a reduction in Gnmt
expression, associated with the induction of miR-873-5p
(Suppl. Fig. 1C). Additionally, in two models of cholestatic
liver disease induced by BDL after 3 and 7 days of sur-
gery14 and the Mdr2-/- mouse, a model of inflammation-
induced cholestatic liver injury, fibrosis, and cancer15, we
found an inverse correlation between GNMT levels and
miR-873-5p expression (Fig. 1c, d).
Likewise, an inverse correlation between hepatic
GNMT expression and miR-873-5p was identified in a
group of 16 cirrhotic patients of diverse etiology (Suppl.
Table 1, Fig. 2a). These results prompted us to assay
circulating miR-873-5p levels in cirrhotic patients. Blood
samples were collected at the screening visit in 35 cir-
rhotic patients diagnosed with cirrhosis or advanced
scaring (F4) with diverse etiology and levels of circulating
miR-873-5p were evaluated and compared to nine healthy
controls. Higher miR-873-5p levels in serum were
observed in cirrhotic patients (Fig. 2b). Subsequently, we
analyzed circulating miR-873-5p levels in a cohort of
cholestatic patients primary biliary cholangitis (PBC)/
primary sclerosing cholangitis (PSC) (n= 41) and com-
pared to healthy patients with antimitochondrial anti-
bodies (AMA+ ) but without abnormal liver test (Suppl.
Table II). In these patients, whose circulating miR-873-5p
levels are increased relative to healthy controls, a positive
correlation was also found with fibrosis grade (Fig. 2c).
Furthermore, a reduction of hepatic GNMT expression
was associated with the fibrosis grade in a cohort of 64
liver cholestasis patients (Suppl. Table III and Fig. 2d).
Finally, a significant correlation between reduced
expression of hepatic GNMT and increased levels of miR-
873-5p in the serum of a cohort of patients with early and
advance cholestatic liver disease was detected in 19 paired
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Fig. 1 MiR-873-5p regulates GNMT expression by post-transcriptional repression and miR-873-GNMT levels are negatively correlated in
mouse liver cholestasis. (a) Luciferase reporter assay of Gnmt 3ʹUTR expression in hepatocytes transfected with mimic-miR-873-5p (N= 8).
(b) GNMT and miR-873-5p expression at mRNA and protein levels in primary hepatocyte after mimic-miR-873-5p transfection. Gnmt-miR-873-5p
expression and correlation and WB analysis of GNMT at different time points of BDL (N= 3) (c) and in Mdr2WT and Mdr2-/- mice at different ages
(3,4,9,12,17 months each column and 3▲, 4▼, 9♦, 12●, and 17■ months in the correlation panel) (N= 3) (d). Densitometry analyses of WB are
shown in Supp. Fig. 1B, D, E. Data normalized as fold change vs. control. Error bars represent the means ± SEM. Statistical significance was determined
by the Student’s t-test or ANOVA when more than two groups were compared. p < 0.05*; p < 0.01**; p < 0.001***
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Fig. 2 MiR-873-5p correlates with liver fibrosis development through the regulation of GNMT in the liver. Hepatic GNMT-miR-873-5p
expression and correlation in a cohort of cirrhotic patients (N= 16) (a) and circulating miR-873-5p in cirrhotic patients (N= 35) (b). (c) Circulating miR-873-
5p levels in cholestatic (PBC/PSC) patients (41) and its correlation with fibrosis (LSM, kPa). (d) GNMT levels in cholestatic patients (N= 64). (e) Correlation
between circulating miR-873-5p and hepatic GNMT in cholestatic patients (N= 19). (f) Correlation between circulating miR-873-5p and hepatic GNMT
with fibrotic stage in cholestatic patients, respectively. Data normalized as fold change vs. control. Error bars represent the means ± SEM. Statistical
significance was determined by the Student’s t-test or ANOVA when more than two groups were compared. p< 0.05*; p < 0.01**; p < 0.001***
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samples (Fig. 2e). Fibrotic stage positively correlated with
miR-873-5p and negatively correlated with GNMT levels
(Fig. 2f). Overall, miR-873-5p expression is augmented
and inversely correlated with hepatic GNMT expression
in cirrhosis and cholestatic disease.
Anti-miR-873-5p attenuates liver injury after bile duct
ligation
The potential benefit of targeting miR-873-5p was
evaluated in the BDL animal model of cholestasis. Thus,
we performed BDL surgery for one week in Gnmt wild-
type (WT) mice and injected anti-miR-873-5p or a miR-
Ctrl i.v. at day 3 and 5, corresponding to the initial phase
of hepatic fibrogenesis14 (Fig. 3a and Suppl Fig. 2A) and
sacrificed animals at 7 days after BDL. MiR-873-5p inhi-
bition (Fig. 3b) resulted in GNMT restoration levels
(Fig. 3c). No effect on miR-873-5p and Gnmt mRNA
levels was detected in other tissues where Gnmt is usually
expressed, such as pancreas and kidney, after miR-873-5p
inhibition (data not shown). Anti-miR-873-5p treatment
was associated with reduced serum transaminases (ALT/
AST), caspase 3 activity and PARP cleavage as well as
parenchymal disruption as detected by H&E staining, all
readouts of cell death (Fig. 3d–f).
In the BDL mouse model, cholangiocyte proliferation
and liver inflammation play essential roles during the
progression of fibrosis that is linked to BA-induced
hepatocyte cell death. Anti-miR-873-5p treatment in vivo
significantly reduced the proliferation of cholangiocytes as
evaluated by cytokeratin 19 (CK19) levels (Fig. 3f) and
counteracted the expression of markers related with
cholangiocyte activation, such as monocyte chemoat-
tractant protein (Mcp-1) and epithelial cell adhesion
molecule (Epcam) (Fig. 3g). Moreover, miR-873-5p inhi-
bition minimized inflammatory markers such as F4/80,
inducible nitric oxide synthase (iNos), acute phase
response gene serum amyloid A1 (Saa1), interleukin-6
(Il-6), and JNK phosphorylation (Fig. 3f–h). Indeed, tumor
necrosis factor (Tnf) and Il-6 reduction (Fig. 3g) modu-
lated STAT3 activation after miR-873-5p inhibition
(Fig. 3h). Finally, in miR-873-5p-inhibited BDL mice,
fibrogenic indicators such as Sirius red, alpha smooth
muscle actin (α-SMA), metalloproteinase 9 (Mmp9),
transforming growth factor beta (Tgfb), and Smad2/3
phosphorylation were significantly reduced in comparison
to those mice treated with miR-Control (Fig. 3f–h).
RNA sequencing analysis further retrieved a completely
different gene ontology (GO) profile in the BDL model
after miR-873-5p inhibition. During this initial phase of
hepatic fibrogenesis, biological processes related to cell
proliferation, natural killer cell activation, and immune
response processes were downregulated in anti-miR-873-
5p vs. miR-Ctrl mice. On the other hand, anti-miR-873-
5p-treated-mice showed increased gene expression
related to biological processes implicated in steroid and
fatty acid metabolism and in the respiratory electron
transport chain compared to miR-ctrl mice (Supp. Fig. 3A
and Supp. Table IV and V).
Of relevance, the treatment of Gnmt-/- mice after 3 and
5 days of BDL with anti-miR-873-5p failed to counteract
both inflammation and fibrosis (Supp Fig. 4a), indicating
that Gnmt is one of the principal targets that mediates the
anti-miR-873-5p effect in vivo, even though miR-873-5p
could affect many different mRNAs besides Gnmt.
Overall, these data show that miR-873-5p inhibition is
hepatoprotective and reduces cell death, affects ductular
reaction and prevents the generation of liver inflamma-
tion and fibrosis after BDL, which is suggested to take
place by enhancing GNMT expression.
MiR-873-5p directly regulates hepatocyte apoptosis and
cholangiocyte proliferation
In the pathology of liver fibrosis and in cholestatic liver
injury different types of hepatic cells including hepato-
cytes, cholangiocytes, inflammatory macrophages (Kupf-
fer cells)16 and Natural Killer7,17–19 cells, and hepatic
stellate cells (HSC)20 are known to mediate different
effects, regulating the development and the progression of
the disease. During initiation of fibrogenesis, hepatocyte
apoptosis and cholangiocyte proliferation are the primary
events driving disease progression14. Although GNMT in
the liver is known to be mainly found in hepatocytes, it
has been described to be expressed in other cell types
such as cholangiocytes, where its expression is associated
with a differentiated and a non-proliferative phenotype of
these cells2. Thus, we have analyzed the targeting of Gnmt
by miR-873-5p in these cells and its potential contribution
to cholestatic liver injury.
Firstly, primary isolated murine hepatocytes were cul-
tured with the toxic bile acid deoxycholic acid (DCA, 100
µM) for 2 h to induce hepatocyte apoptosis, an in vitro cell
model that mimics in vivo BDL. Under these circum-
stances, DCA treatment was associated with reduced
Gnmt expression together with the induction of miR-873-
5p and hepatocyte apoptosis, suggesting the importance
of the regulation of GNMT-miR-873-5p axis in hepato-
cytes (Fig. 4a). The potential role of miR-873-5p in the
induction of BA-induced apoptosis in hepatocytes
through the repression of Gnmt was studied by inhibiting
miR-873-5p directly in these cells. MiR-873-5p inhibition
in hepatocytes induced GNMT levels (Fig. 4b), resulting
in attenuation of BA-induced apoptosis measured by
Caspase 3 activity, TUNEL assay and JNK phosphoryla-
tion (Fig. 4c, d). Moreover, miR-873-5p inhibition
increased the expression of different genes related to BA-
induced apoptosis [B-Cell CLL/Lymphoma 2 (Bcl2) and
the Hepatocyte nuclear factor (Hnf) Hnf1α and Hnf4α]
and, more importantly, genes implicated in BA
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Fig. 3 (See legend on next page.)
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metabolism and regulation, such as the master regulator
of BA metabolism Fxr and different BA exporters, such as
Bsep, Abcg5 and some Mdr/Mrp (Fig. 4e).
Then, GNMT targeting by miR-873-5p was evaluated in
cholangiocyte cell lines. It has been reported that
inflammatory mediators like IL-6 (significantly aug-
mented after BDL and modulated in the presence of anti-
miR-873-5p (Fig. 3g)) induces cholangiocyte proliferation.
Indeed, the normal human cholangiocyte cell line NHC
incubated with IL-6 show increased miR-873-5p expres-
sion (Fig. 4f). MiR-873-5p inhibition reduced cholangio-
cyte proliferation measured by MTT assay and the levels
of cyclin D1 (CD1) and proliferating cell nuclear antigen
(PCNA) (Fig. 4f). Furthermore, anti-miR-873-5p increased
GNMT expression and minimized the levels of growth
factors (TGFβ and platelet derived growth factor (PDGF))
implicated in cholangiocyte contribution to BDL-induced
fibrosis (Fig. 4f).
Overall, these data suggest that anti-miR-873-5p has
broad effects in liver cells affecting fibrosis progression,
mainly mediating anti-apoptotic activity in hepatocytes
and anti-proliferative effect in cholangiocytes contributing
to reduce liver injury and fibrosis progression.
Anti-miR-873-5p prevents liver injury in Mdr2-/- mice
Mice lacking the ATP-binding cassette ABCB4 protein
encoded by the Mdr2 gene (Mdr2-/-) provide a model for
the study of cholestasis in the context of chronic inflam-
mation as a result of increased BA accumulation15. The
increase in miR-873-5p and the low expression levels of
GNMT at the different stages of hepatic fibrogenesis in
the Mdr2-/- mice (Fig. 1d) prompted us to investigate the
impact that anti-miR-873-5p treatment could have in this
model. Four-month old Mdr2-/- mice, with advanced
fibrosis and biliary proliferation (Suppl Fig. 6a), were
treated once a week with anti-miR-873-5p during 4 weeks
(Fig. 5a). Anti-miR-873-5p treatment rescued GNMT
(Fig. 5b, c) and reduced ALT/AST transaminases, total
serum BA levels (Fig. 5d, e), cholangiocytes proliferation
by CK19, hepatocyte death assessed by caspase 3 activity
and hepatic ammonia content21 (Fig. 5f). Moreover,
Mdr2-/- mice treated with anti-miR-873-5p showed lower
cell death receptor Dr5 and higher biliary acids trans-
porters of the ABC superfamily Mdr1, Mrp3, and Mrp5
(Suppl Fig. 6B), consistent with the reduction of BA
content, BA-induced apoptosis and markers related to
cholangiocyte activation (Suppl Fig. 6B). These changes
were accompanied by a reduced inflammatory response as
determined by F4/80 and Il-6, Ccl1 and iNos expression,
as well as less fibrosis evaluated through Sirius red
staining and the levels of profibrogenic (Tgfb, Timp1, and
Timp2) genes (Fig. 5f and Suppl Fig. 6b). Altogether, these
data suggest that anti-miR-873-5p targeting in the
Mdr2-/-cholestasis animal model reduces cholangiocyte
proliferation, increases the export of bile acids and ame-
liorates BA-induced hepatocyte cell death and inflam-
matory response.
MiR-873-5p regulation results in GNMT-dependent
epigenomic modulation
DNA (CpG) methylation acts as a blueprint for global
alterations in the epigenome that drive liver injury22
among them hepatic fibrogenesis23–26. BDL and Mdr2-/-
mice under anti-miR-873-5p treatment showed improved
hepatic SAMe metabolism with a decrease in the ratio
SAMe/S-adenosylhomocysteine (SAH) consistent with
the re-expression of GNMT (Table 1). This effect in the
methylation flux correlated with a reduction in the global
DNA methylation content as detected after miR-873-5p
inhibition (Fig. 6a). DNA methylation is mediated by two
groups of DNA methyltransferases (DNMTs), DNMT1
that is implicated in maintenance of DNA methylation
and DNMT3a/3b that are responsible for de novo DNA
methylation27. According to the changes in DNA
methylation levels in the liver, anti-miR-873-5p treatment
reduced Dnmt3a expression in both fibrotic animal
models (Fig. 6b). Indeed, the inhibition of miR-873-5p
during BDL and in Mdr2-/- mice increased the expression
of other genes of the methionine cycle besides Gnmt, such
as Methionine adenosyltransferase (Mat1a) and
S-adenosylhomocysteine hydrolase (Sahh) (Suppl.
Fig. 7A).
Different genes could be regulated by methylation of
their CpG islands. The activity of STAT3, a key player in
liver inflammation, was repressed in BDL under miR-873-
5p inhibition (Fig. 3g), correlating with the re-expression
of its inhibitor Protein inhibitor of activated STAT (Pias)
Pias 1/3 (Fig. 6c), that has been associated to its promoter
(see figure on previous page)
Fig. 3 Anti-miR-873-5p attenuates BDL-induced liver injury through GNMT regulation. (a) Time scheme of the BDL mouse model with anti-
miR-873-5p (time points indicated). MiR-873-5p expression (b) and GNMT mRNA and protein expression (c) in the liver of miR-Ctrl-BDL and anti-miR-
873-5p-BDL mice. (d) Serum transaminases (ALT and AST) levels in miR-Ctrl and anti-miR-873-5p-treated-mice at 7 days of BDL. (e) Caspase 3 activity
and WB analysis of apoptosis mediated by PARP cleavage. (f) H&E, F4/80, Sirius Red, αSMA, and CK19 staining in liver sections from miR-Ctrl and miR-
873-5p-inhibited-mice at 7 days of BDL. (g) qPCR analysis of indicated genes in total liver extracts at 7 days of BDL. (h) WB analysis with indicated Ab
in total liver of WT, BDL-Ctrl and anti-miR-873-BDL mice at 7 days. Densitometry analyses of WB are shown in Supp. Fig. 2B. Data normalized as fold
change vs. control. Error bars represent the means ± SEM (N= 4). Statistical significance was determined by the Student’s t-test or ANOVA when
more than two groups were compared. p < 0.05*; p < 0.01**; p < 0.001***
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Fig. 4 MiR-873-5p regulates hepatocyte apoptosis and cholangiocyte proliferation by targeting GNMT. (a) Gnmt and miR-873-5p expression
in cultured hepatocytes treated with deoxycholic acid (DCA) for 2 h (N= 3). (b) GNMT expression analysis by qPCR and WB after anti-miR-873-5p and
DCA treatment. Cell death was measured by C3 activity (2 h) TUNEL and JNK phosphorylation (15’/30’) at different time points of DCA treatment (c, d).
(e) Gene expression analysis by qPCR of indicated genes implicated in BA-induced apoptosis, metabolism and transport after 2 h of DCA and anti-
miR.873-5p treatment (N= 3). Densitometry analyses of WB are shown in Supp. Fig. 5A. (f) MiR-873-5p expression in normal human cholangiocytes
(NHC) after 48 h of Interleukin-6 (IL-6) treatment (N= 6). Cell proliferation measured by MTT assay and analysis of GNMT and indicated genes
measured by qPCR in anti-miR-873-5p cholangiocytes treated with IL-6 (N= 4). Data normalized as fold change vs. control. Error bars represent
the means ± SEM. Statistical significance was determined by the Student’s t-test or ANOVA when more than two groups were compared. p < 0.05*;
p < 0.01**; p < 0.001***
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methylation status28. Similarly, the promoter regulation of
RAS-association domain family (RASSF) (inhibitors of
RAS signaling), has been reported to be susceptible of
hypermethylation in the absence of GNMT8 and in early
HCCs28. We have found that the expressions of RASSF
genes (Rassf1a/Rassf4a) are upregulated in Mdr2-/- mice
after blockade of miR-873-5p (Fig. 6c).
Regulation of cholangiocyte proliferation and BA
metabolism have both been described to be under epi-
genetic control29,30. SRY-Box 17 (SOX17) regulates the
phenotype of normal human cholangiocytes acting as a
tumor suppressor in cholangiocarcinoma, occurring its
downregulation through DNA methylation31. Under anti-
miR-873-5p treatment, Sox17 expression was significantly
upregulated in BDL and Mdr2-/- mice (Fig. 6d). Finally,
inhibiting miR-873-5p also restored the expression of
genes methylated under pathological conditions, such as
Abcg5 and Bsep, as well as the nuclear receptors Shp and
Fxr, implicated in BA transport and metabolism29
(Fig. 6e).
Besides DNA, SAMe can methylate histones at different
residues. Histone modification is also involved in estab-
lishing patterns of gene repression during liver injury.
Methylation of histones and DNA are linked to the acti-
vation of HSCs32. Importantly, miR-873-5p inhibition
significantly reduced the protein levels of EZH2, a profi-
brogenic histone lysine methyltransferase, after BDL and
in Mdr2-/- mice (Fig. 6f). Also, the mRNA level of the
histone methyltransferase Ash1 is reduced after anti-miR-
873-5p treatment, correlating with the decrease in the
methylation level of its target H3K4, which has been
related with TGFβ induction in fibrosis (Suppl. Fig. 6B)33.
Overall, these data suggest that the prompt recuperation
of hepatic GNMT expression through anti-miR-873-5p
treatment could lead to the restoration of SAMe meta-
bolism and the epigenetic regulation of specific genes that
are implicated directly in BA homeostasis, cholangiocyte
proliferation and inflammatory and fibrogenic pathways
(Fig. 7).
Discussion
GNMT is considered a major regulator of the trans-
methylation flux in the liver controlling liver homeostasis
and health4,5. A decrease in GNMT levels occurs in
NAFLD, at early stages of fibrosis, cirrhosis, and
HCC1,6,7,34,35. Data highlighting that attenuation of
GNMT was found at early stages of liver disease, where
fibrosis is still not prominent, points to GNMT deficiency
as a contributor/mediator of fibrogenesis rather than a
consequence. Even though GNMT repression in some
primary tumors has been associated with aberrant pro-
moter methylation9, hypermethylation does not seem to
be the unique mechanism for GNMT regulation, and it
may coexist with other regulatory pathways9.
miRNAs regulate a wide variety of biological functions
in the liver and are directly implicated in inflammation,
cirrhosis, and malignant transformation13. These small
molecules are, therefore, emerging as viable therapeutic
tools. Three independent unbiased approaches revealed
miR-873-5p as a potential microRNA targeting GNMT. In
here, we have shown that miR-873-5p is modulated in
several in vitro and in vivo models of liver fibrosis where
GNMT levels are modified. Furthermore, in the clinical
setting, we have found high levels of circulating miR-873-
5p in the serum of cirrhotic patients as well as a negative
correlation between hepatic GNMT and miR-873-5p in
human cirrhosis and cholestasis. Altogether, this evidence
allowed us to identify for the first time GNMT as a direct
target of miR-873-5p.
Although liver fibrosis was historically thought to be an
irreversible process, the understanding of its molecular
pathogenesis has stimulated the development of novel
antifibrotic therapies, still in an experimental phase36.
Increased miR-873-5p levels have been observed in
Table 1 Liver SAMe and SAH levels regulation by anti-miR-873-5p in BDL and Mdr2-/- mice
GROUP SAMe (pmol/mg prot) SAH (pmol/mg prot) SAMe/SAH (pmol/mg prot) T-TEST SIGNIFICANCE
(SAMe/SAH ratio)
BDL MICE
Wt 109.06 ± 42.36 63.22 ± 12.03 1.75 ± 0.72
miR-Ctrl BDL 158.61 ± 34.32 41.30 ± 13.93 4.00 ± 1.11 0.042a
Anti-miR-873-5p-BDL 108.80 ± 38.99 58.97 ± 7.57 1.86 ± 0.67 0.046b
Mdr2-/- MICE
miR-Ctrl 61.81 ± 4.35 2.55 ± 0.41 21.12 ± 2.75
Anti-miR-873-5p 53.03 ± 10.22 3.27 ± 06.8 16.58 ± 3.19 0.034c
ap CTRL vs. miR-Ctrl BDL
bp miR-Ctrl BDL vs. anti-miR-873-5p BDL
cp Mdr2-/- miR-Ctrl vs. anti-miR-873-5p
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Fig. 5 Anti-miR-873-5p decreases hepatocyte apoptosis, cholangiocyte proliferation, inflammation, and fibrogenesis in Mdr2-/- mice.
(a) Time scheme of the anti-miR-873-5p treatment in Mdr2-/- mice (time points indicated). MiR-873-5p (b) and GNMT expression (c) in the liver of
Mdr2-/- and anti-miR-873-Mdr2-/- mice. (d) Serum transaminases levels expressed as fold change from the initial values and (e) bile acid content in
Mdr2-/- mice. (f) CK19, Cleaved Caspase 3, ammonia, F4/80, and Sirius red staining in liver sections from miR-Ctrl and miR-873-5p-inhibited Mdr2 -/-
mice. Densitometry analyses of WB are shown in Supp. Fig. 6C. Data normalized as fold change vs. control. Error bars represent the means ± SEM
(N= 5). Statistical significance was determined by the Student’s t-test or ANOVA when more than two groups were compared p < 0.05*; p < 0.01**;
p < 0.001 ***. ----- line in d indicates initial levels of the measurements
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Fig. 6 Epigenomic alterations contributing to liver fibrosis are reverted in anti-miR-873-5p-treated-mice through the restoration of GNMT,
SAMe metabolism, and transmethylation flux. (a) DNA CpG (5mC) methylation in Ctrl and BDL/anti-miR-873-BDL livers (N= 4). qPCR and WB
analysis of genes implicated in DNA methylation (b). qPCR analysis of indicated genes susceptible of promoter hypermethylation related to
cholangiocyte proliferation and bile acid metabolism (c-e) in miR-Ctrl and anti-miR-873-5p BDL/Mdr2-/- mice (N= 4 (BDL) and N= 5 (Mdr2-/-). (f) WB
analysis of EZH2 in anti-miR-873-5p-BDL/Mdr2-/- mice (N= 4 (BDL) and N= 5 (Mdr2-/-). Densitometry analyses of WB are shown in Supp. Fig. 7C. Data
normalized as fold change vs. control. Error bars represent the means ± SEM. Statistical significance was determined by the Student’s t-test or ANOVA
when more than two groups were compared. p < 0.05*; p < 0.01**; p < 0.001***
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hepatocytes and in proliferative cholangiocytes under
cholestatic/fibrogenic situations. Anti-miR-873-5p treat-
ment in vitro decreased the BA-induced hepatocyte cell
death as well as cholangiocyte proliferation. Importantly,
anti-miR-873-5p treatment in Gnmt wild-type mouse
submitted to BDL surgery blocked the overwhelming
inflammatory profile associated to fibrosis. Of relevance,
no effects under miR-873-5p inhibition were detected in
the Gnmt-/- mice, indicating that GNMT activity is the
hub of the regulatory network modulated by miR-873-5p.
In the Mdr2-/- cholestatic mouse model inhibition of
miR-873-5p for only 4 weeks starting at the time at which
an overt inflammation, cholestasis, and severe fibrosis is
observed (4 months old mice), resulted in reduced BA-
related cell death and cholangiocyte proliferation, with
mild blunted inflammation and decreased fibrosis related
markers.
DNA methylation and hydroxymethylation are epige-
netic mechanisms that modulate gene expression and play
a critical role in the development of liver fibrosis22,24–26.
We have identified that miR-873-5p changes methyl-
transferase signaling and DNA methylation state during
BDL-mediated hepatic injury and in the chronic model of
Mdr2-/- mice. Anti-miR-873-5p therapy restores the
transmethylation flux to normal levels in both animal
models of liver damage. This miR-873-5p-dependent
modulation of the methylome reduces global DNA
methylation by decreasing Dnmt3a expression that func-
tions as a de novo methyltransferase24. DNA methylation
changes that occur in the livers of mice under anti-miR-
Fig. 7 MiR-873-5p targets GNMT expression in the liver mediating global epigenomic changes and contributing to liver fibrosis
progression
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873-5p treatment are associated with altered expression of
specific genes. Indeed, in BDL mouse, anti-miR-873-5p
restores Pias 1,3 levels, genes highly sensible to methy-
lation changes and regulators of STAT3 phosphorylation
with the concomitant regression of the inflammatory
response. The reduction in STAT3 activation observed in
BDL mouse after anti-miR-873-5p treatment, could also
have an important effect in the amelioration of fibrosis,
due to its direct role in promoting HSC, the major
fibrogenic cell type37. InMdr2-/- mice, the upregulation of
the RASSF tumor suppressor, also susceptible to epige-
netic modification linked to miR-873-5p treatment,
blocks the Ras/Raf/MEK/ERK pathway, related to tumor
formation38.
Hepatic fibrosis is also related to methylation changes in
BA metabolism and cholangiocyte proliferation29. BAs are
highly cytotoxic, their synthesis, transport, and pool size
are tightly regulated under physiological conditions. FXR,
implicated in every step of BA homeostasis and suscep-
tible to be regulated by methylation29, was upregulated
under anti-miR-873-5p treatment. FXR has been shown
to induce BSEP and MRP2 in hepatocytes39. Importantly,
the inhibition of miR-873-5p counteracts the repression
of BSEP and the basolateral drug transporters MRP3 and
MRP4 in our cholestatic models. Thus, the stimulation of
basolateral BA efflux may be an important protective
response against the cholestatic liver injury detected in
BDL and Mdr2-/- that could also be regulated by DNA
methylation of different genes. Regarding cholangiocyte
proliferation, SOX17 promoter was previously found to be
hypermethylated and downregulated in cholangiocarci-
noma31. In addition, downregulation of SOX17 is impli-
cated in cholangiocyte damage and fibrosis40. MiR-873-5p
therapy is able to re-express Sox17 in both cholestatic
animal models potentially regulating cholangiocyte
proliferation.
Finally, the activation of HSC to myofibroblast is a key
process in liver fibrosis mediated by epigenetic mechan-
ism41. We now provide evidence that SAMe flux recovery
mediated by anti-miR-873-5p treatment and GNMT
rescue reduced EZH2 levels. This histone methyl-
transferase is one of the major regulators for profibro-
genic factors42. Moreover, other signatures of histone
methylation are observed in the BDL model, including
changes in the histone methyltransferase Ash1, correlating
with methylation of the histone H3K4, which has been
related with TGFβ induction of fibrosis33.Therefore, it is
tempting to hypothesize that changes in global methyla-
tion seen after GNMT recovery could exert a negative
feedback in the transdifferentiation and activation of HSC.
Our results show that miR-873-5p inhibition directly
regulates in vivo BA metabolism, cholangiocyte pro-
liferation and activation and hepatocyte cell death. Mod-
ulation of hepatocyte cell death by inhibiting miR-873-5p
further reduces inflammatory responses and ameliorates
the fibrotic phenotype in diverse liver injury mouse
models, possibly associated with epigenetic changes
(Fig. 7). Indeed, there is an emerging field in the screening
of epi-drugs in the fibrosis disease.
Summing up, the significant inverse correlation
between hepatic GNMT and miR-873-5p expression both
in cirrhotic and cholestatic patients targeting the miR-
873-5p/GNMT axis may provide a novel therapeutic
approach to treat liver fibrosis.
Materials and methods
Human studies
All the studies were performed in agreement with the
Declaration of Helsinki, and with local and national laws.
The Human Ethics Committee of Valdecilla Hospital and
of the University of Navarra approved the study
procedures.
Cirrhotic patients
Cohort 1
Sixteen liver samples from cirrhotic patients (grade F4)
of diverse etiologies were included in this study. The
characteristics of these patients are summarized in Suppl.
Table I. Healthy liver samples (from individuals with
normal or minimal changes in the liver) were collected at
surgery of digestive tumors or from percutaneous liver
biopsy performed because of mild alterations of liver
function. All samples were obtained from the Biobank of
the University of Navarra (Pamplona, Spain).
Cohort 2
Thirty-five serum samples from cirrhotic patients (grade
F4) (45.7% women and 54.3% men, mean age 63.9 ± 13.4
years) were included in this study from patients recruited
ate the Marqués de Valdecilla University Hospital
(MVUH, Santander, Spain). Cirrhosis diagnosis was
established by clinical or histological data. Etiology was
varied: 43% hepatitis C, 31% alcoholic, 17% autoimmune
hepatitis, 6% primary biliary cholangitis and 3% hepatitis
B. Serum samples (n= 9; five women and four men, mean
age 32.4 ± 6.4 years) from healthy volunteer subjects were
used as controls and recruited through the Gastro-
enterology and Hepatology Department of MVUH, San-
tander, Spain.
Cholestatic patients
Cohort 3
Forty-one serum samples from cholestatic patients
(PBC= 36; PSC= 5) with different grade of fibrosis (early
= 34; advanced= 7) were included in the study (90%
women and 10% men, mean age 59.5 ± 12.2 years). PBC/
PSC diagnosis was established in MVUH and based on
clinical and biochemical data, immunological markers,
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imaging, liver histology, and exclusion of other possible
causes of liver injury. Healthy human serum samples
(n= 13) (92% women and 8% men, mean age 45.5 ± 10.5)
from subjects with AMA in serum and without abnormal
liver test were included and provided by the Gastro-
enterology and Hepatology Department MVUH, Santan-
der, Spain. Characteristics of these patients are
summarized in Suppl. Table II.
Cohort 4
Sixty-four liver samples from patients with cholestatic
liver disease, PBC (n= 60) and PSC (n= 4) were included
in this study (90% women and 10% men, mean age 51.64
± 10.65 years). PBC/PSC diagnosis, established in Mar-
qués de Valdecilla University Hospital (MVUH, Santan-
der, Spain), was based on clinical and biochemical data,
immunological markers, imaging, liver histology, and
exclusion of other possible causes of liver injury. Patients
were classified for early or advance fibrosis based on
histological analysis and according to Ludwig classifica-
tion stage (Grade I–IV). Characteristics of these patients
are summarized in Suppl. Table III. Healthy human liver
samples (n= 12; 42% women and 58% men, mean age
63.16 ± 13.01 years) from organ-transplant donor were
used as controls and recruited through the Gastro-
enterology and Hepatology Department of MVUH, San-
tander, Spain.
Animal studies
Three-month-old male (C57BL6), Gnmt wild type
(WT), Gnmt-knockout (Gnmt-/-) and Mdr2-/- and
Mdr2WT mice were used15,43. Animal procedures were
approved by CIC bioGUNE’s Animal Care and Use
Committee and the competent authority (Diputación de
Bizkaia, Spain).
In vivo miR-873-5p inhibition after BDL
Three-month-old male Gnmt WT and Gnmt-/- mice
were injected in the tail vein with miRIDIAN microRNA
Hairpin Inhibitor anti-miR-873-5p or miR-Control (60
µg/mouse) (Dharmacon, USA) at 3 days after BDL and
repeated on day 5 using Invivofectamine 3.0, following the
manufacturer’s instructions (Invitrogen, USA). Mice were
sacrificed at day 7, blood withdrawn and livers removed
and snap frozen in liquid nitrogen or fixed in formalin for
subsequent analysis.
In vivo miR-873-5p inhibition in Mdr2-/- mice
Four-month-old male Mdr2-/- mice were injected in the
tail vein with miRIDIAN anti-miR-873-5p or miR-Control
(60 µg/mouse) once a week during 4 weeks using Invi-
vofectamine 3.0, following the manufacturer’s instructions
(Invitrogen, USA). Animals were then sacrificed, blood
withdrawn and livers were removed and snap frozen in
liquid nitrogen or fixed in formalin.
In vitro miR-873-5p inhibition
Mouse primary hepatocytes were isolated from male
Gnmt WT mice via collagenase perfusion as described44.
All adhered cells were maintained in MEM with 10% fetal
bovine serum (FBS). NHC cholangiocytes and primary
mouse hepatocytes were transfected with anti-miR-873-
5p or a miR-Control using DharmaFECT transfection
reagent (Dharmacon) following the manufacturer’s
procedure.
SAMe and SAH measurement
Hepatic SAMe and SAH were determined by Liquid-
chromatography/mass spectrometry (LC/MS) using a
Waters ACQUITY-UPLC system coupled to a Waters
Micromass LCT Premier Mass Spectrometer equipped
with a Lockspray ionization source as described
previously45.
Global DNA methylation measurement
Global DNA methylation (5mC) analyses were per-
formed following the method previously described46.
Bile acids (BA) measurement
Total bile acids in serum of Mdr2-/- mice were mea-
sured using the Total Bile Acid Assay Kit (Cell Biolabs,
Inc, USA) following the manufacturer’s instructions.
Statistical analysis
Data are represented as mean ± SEM. mRNA/RNA data
is normalized as fold change vs. control. Statistical sig-
nificance was determined by the Student’s t-test when
two groups were compared and when comparing three
groups one-way analysis of variance (ANOVA) was used.
A p < 0.05 was considered significant.
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